GLP-1 drugs are increasingly moving into gastroenterology conversations—not just for obesity and diabetes, but for conditions like MASLD, GERD, and even inflammatory bowel disease, where some clinicians are observing symptom improvement in select patients.
The article raises a broader question: should gastroenterologists begin prescribing GLP-1s themselves, or should these therapies remain primarily managed by primary care and endocrinology? While enthusiasm around the drugs continues to grow, experts also emphasize the need for GI physicians to understand their gastrointestinal side effects, safety considerations, and potential long-term role in GI disease prevention, including possible effects on GI cancer risk.